DEXCOM INC (DC4.DE) Stock Overview
Europe - FRA:DC4 - US2521311074 - Common Stock
DC4.DE Key Statistics, Chart & Performance
The current stock price of DC4.DE is 59.2 EUR. In the past month the price increased by 0.44%. In the past year, price decreased by -10.02%.
DC4.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABL.DE | ABBOTT LABORATORIES | 25.69 | 192.29B | ||
| IUI1.DE | INTUITIVE SURGICAL INC | 57.77 | 143.73B | ||
| 1ISRG.MI | INTUITIVE SURGICAL INC | 57.72 | 143.61B | ||
| BSX.DE | BOSTON SCIENTIFIC CORP | 35.25 | 127.43B | ||
| 1MDT.MI | MEDTRONIC PLC | 17.43 | 106.40B | ||
| 2M6.DE | MEDTRONIC PLC | 17.34 | 105.89B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 20.68 | 55.53B | ||
| BOX.DE | BECTON DICKINSON AND CO | 13.23 | 46.62B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 29.5 | 38.28B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 17.06 | 23.66B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 17.23 | 23.89B | ||
| QS51.DE | STRAUMANN HOLDING AG-REG | 33.53 | 15.29B |
Related stock screener links
About DC4.DE
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA US
Employees: 10300
Phone: 18582000200
DEXCOM INC / DC4.DE FAQ
What is the stock price of DEXCOM INC today?
The current stock price of DC4.DE is 59.2 EUR. The price increased by 2.97% in the last trading session.
What is the ticker symbol for DEXCOM INC stock?
The exchange symbol of DEXCOM INC is DC4 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is DC4.DE stock listed?
DC4.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for DEXCOM INC stock?
35 analysts have analysed DC4.DE and the average price target is 89.5 EUR. This implies a price increase of 51.19% is expected in the next year compared to the current price of 59.2. Check the DEXCOM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DEXCOM INC worth?
DEXCOM INC (DC4.DE) has a market capitalization of 23.22B EUR. This makes DC4.DE a Large Cap stock.
How many employees does DEXCOM INC have?
DEXCOM INC (DC4.DE) currently has 10300 employees.
What are the support and resistance levels for DEXCOM INC (DC4.DE) stock?
DEXCOM INC (DC4.DE) has a support level at 57.27 and a resistance level at 59.21. Check the full technical report for a detailed analysis of DC4.DE support and resistance levels.
Is DEXCOM INC (DC4.DE) expected to grow?
The Revenue of DEXCOM INC (DC4.DE) is expected to grow by 14.99% in the next year. Check the estimates tab for more information on the DC4.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DEXCOM INC (DC4.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DC4.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DC4.DE, evaluating the profitability, health, valuation and growth aspects
- DEXCOM INC (DC4.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DEXCOM INC (DC4.DE) Sales and EPS estimates to see what analysts future expectations are.
- DEXCOM INC (DC4.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DEXCOM INC (DC4.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- DEXCOM INC (DC4.DE) Stock Chart to make your own analysis
- DEXCOM INC (DC4.DE) Latest news and press-releases to stay up to date.
Does DEXCOM INC (DC4.DE) stock pay dividends?
DC4.DE does not pay a dividend.
When does DEXCOM INC (DC4.DE) report earnings?
DEXCOM INC (DC4.DE) will report earnings on 2025-10-30, after the market close.
What is the Price/Earnings (PE) ratio of DEXCOM INC (DC4.DE)?
The PE ratio for DEXCOM INC (DC4.DE) is 40.55. This is based on the reported non-GAAP earnings per share of 1.46 and the current share price of 59.2 EUR. Check the full fundamental report for a full analysis of the valuation metrics for DC4.DE.
DC4.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DC4.DE. When comparing the yearly performance of all stocks, DC4.DE is a bad performer in the overall market: 91.21% of all stocks are doing better.
DC4.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE. While DC4.DE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
DC4.DE Financial Highlights
Over the last trailing twelve months DC4.DE reported a non-GAAP Earnings per Share(EPS) of 1.46. The EPS decreased by -2.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.29% | ||
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| Debt/Equity | 0.5 |
DC4.DE Forecast & Estimates
35 analysts have analysed DC4.DE and the average price target is 89.5 EUR. This implies a price increase of 51.19% is expected in the next year compared to the current price of 59.2.
For the next year, analysts expect an EPS growth of 26.84% and a revenue growth 14.99% for DC4.DE